Incyte announced the approval of Jakafi (ruxolitinib)
MAGE
(BMC) (r)
| Price | 17.22 |
| Price Change Today | -$0.20 (-1.15%) |
| P&P rating | ![]() |
| Zacks Rank | 3 - HOLD |
| Open Price | $17.39 |
| Previous Close | $17.42 |
| Daily Range | $17.04 - $17.52 |
| 52-Week Range | $11.76 - $21.15 |
| Volume | 1,294,988 |
| Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer. | |





Comments: 0 | Comment
MAGE
(BMC) (r)
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment